Is it possible to reduce cardiovascular risk with glucose-lowering approaches? (Q37483478)

20 August 2017

1 reference

title

Is it possible to reduce cardiovascular risk with glucose-lowering approaches? (English)

1 reference

20 August 2017

0 references

Hertzel C Gerstein

1

0 references

publication date

1 May 2009

1 reference

Nature Reviews Endocrinology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

5

1 reference

20 August 2017

270-275

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2009.49

20 August 2017

0 references

cites work

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Blood glucose and risk of cardiovascular disease in the Asia Pacific region

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. The example of albuminuria and the risk of cardiovascular disease in diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Effects of intensive glucose lowering in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Glucose control and vascular complications in veterans with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

10-year follow-up of intensive glucose control in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Rosiglitazone RECORD study: glucose control outcomes at 18 months

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with Type 2 diabetes mellitus (HEART2D) Study design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2009.49

Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19444260

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19444260

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2009.49

1 reference

20 August 2017

1 reference

PubMed ID

19444260